Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12156504 | 0.87 | CASP3 (0.44) | CASP3CASP1PREPALDH1A1GAA | |
| SCHEMBL1841848 | 0.87 | CASP3 (0.44) | CASP3CASP1PREPALDH1A1GAA | |
| SCHEMBL2786342 | 0.87 | CASP3 (0.44) | CASP3CASP1PREPALDH1A1GAA | |
| SCHEMBL12156505 | 0.85 | CASP3 (0.42) | CASP3CASP1PREPCTSKCTSB | |
| SCHEMBL13600773 | 0.85 | CASP3 (0.42) | CASP3CASP1PREPCTSKCTSB | |
| SCHEMBL2341992 | 0.85 | CASP3 (0.41) | CASP3CASP1PREPCTSKCTSB | |
| SCHEMBL13411399 | 0.83 | CASP3 (0.41) | CASP3CASP1PREPCTSKCTSB | |
| SCHEMBL1842398 | 0.83 | CASP3 (0.41) | CASP3CASP1PREPCTSKCTSB | |
| SCHEMBL12156507 | 0.83 | PREP (0.40) | CASP3CASP1PREPCTSKCTSB | |
| SCHEMBL13600774 | 0.83 | PREP (0.40) | CASP3CASP1PREPCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656345-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-10-16 | — | — | EP | disclosed |
| US-7829571-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-14 | — | — | US | disclosed |
| US-7482335-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CARTER PEROY H | 2007-02-08 | — | — | US | disclosed |
| US-7163937-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032526-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | CASP3 4375/4885CASP1 1651/4885PREP 2874/4885 |
| US-20090124668-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | CASP3 4375/4885CASP1 1651/4885PREP 2874/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | CASP3 4375/4885CASP1 1651/4885PREP 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.